Last reviewed · How we verify
Matching vehicle control
Matching vehicle control is a Small molecule drug developed by Pfizer. It is currently in Phase 3 development.
A matching vehicle control is an inert formulation used as a comparator in clinical trials to isolate the effect of the active drug.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Matching vehicle control |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Vehicle controls contain all inactive ingredients and excipients of the active drug formulation but exclude the active pharmaceutical ingredient itself. This allows researchers to distinguish therapeutic effects of the drug from effects caused by the delivery system, excipients, or placebo response. Vehicle controls are particularly important in Phase 3 trials to establish that observed benefits are attributable to the active compound rather than the formulation.
Approved indications
Common side effects
Key clinical trials
- TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD (PHASE1, PHASE2)
- The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis (PHASE3)
- A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). (PHASE1, PHASE2)
- Topical Ketotifen 0.25% for Secondary Vestibulodynia (PHASE2)
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) (PHASE3)
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) (PHASE3)
- Assessment of BHB Concentration Agreement Among Sampling Locations and the Impact of Ketosis on EPO, and More (NA)
- DBM-1152A Inhalation Solution in Chinese Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching vehicle control CI brief — competitive landscape report
- Matching vehicle control updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Matching vehicle control
What is Matching vehicle control?
How does Matching vehicle control work?
Who makes Matching vehicle control?
What development phase is Matching vehicle control in?
Related
- Manufacturer: Pfizer — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing